| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Inhibikase Therapeutics, Inc. (IKT) has 10 insiders with recent SEC Form 4 filings, including 13 buys and 0 sells. IKT is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 13.02M | $26.82M | - | |
| CEO | 4.98M | $10.26M | - | |
| CFO | 986.3K | $2.03M | - | |
| Pres | 900.1K | $1.85M | - | |
| Dir | 108.2K | $222.8K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 21, 2025 | Sands Capital Life Sciences Pulse Fund Ii, L.P. | 10% Owner | Buy | 2,068,965 | $1.45 | $2,999,999.25 | +18.9% | +16.8% | - | |
| Oct 21, 2024 | Kush Arvind | Director | Buy | 145,000 | $1.37 | $198,650.00 | New | +26.6% | -28.8% | |
| Oct 21, 2024 | Munshi Amit | Director | Buy | 365,000 | $1.37 | $500,050.00 | New | +26.6% | -28.8% | |
| Oct 21, 2024 | Bellini Roberto | Director | Buy | 1,460,000 | $1.37 | $2,000,200.00 | New | +26.6% | -28.8% | |
| Aug 16, 2022 | Werner Milton H. | President And CEO | Buy | 5,000 | $0.80 | $4,000.00 | - | -32.3% | -53.2% | |
| May 27, 2022 | Werner Milton H. | President And CEO | Buy | 5,000 | $0.98 | $4,880.00 | - | -6.0% | -34.2% | |
| May 20, 2022 | Werner Milton H. | President And CEO | Buy | 10,000 | $0.60 | $6,000.00 | +0.2% | +22.2% | -2.5% | |
| May 19, 2022 | Frattaroli Joseph | Chief Financial Officer | Buy | 3,948 | $0.64 | $2,542.51 | +8.9% | +30.6% | +1.6% | |
| Nov 17, 2021 | Werner Milton H. | President And CEO | Buy | 23,589 | $1.97 | $46,558.14 | +25.0% | -37.4% | -64.9% |